Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 11:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 9,939 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infectious Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Video-Assisted Counseling for HPV Vaccination

NCT03510091
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Counseling
Behavioral
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
9 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 31, 2026, 11:06 PM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children Infected With or at Risk for HIV Infection

NCT00000984
View directory record Official record
Conditions
HIV Infections
Interventions
CD4 Antigens
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
San Francisco, California • Stanford, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 31, 2026, 11:06 PM EDT
Completed Phase 4 Interventional Results available

Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia

NCT02339038
View directory record Official record
Conditions
HCV HIV
Interventions
Ledipasvir 90 mg and Sofosbuvir 400 mg
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 31, 2026, 11:06 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

NCT03537508
View directory record Official record
Conditions
Healthy Volunteers (Meningococcal Infection)
Interventions
MenACYW conjugate vaccine, MenACYW-135 conjugate vaccine, DTaP-IPV//Hib vaccine, Pneumococcal 13-valent conjugate vaccine, Pentavalent rotavirus vaccine, Hepatitis B vaccine, Measles, mumps, rubella (MMR) vaccine, Varicella vaccine, Hepatitis A vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,627 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
65
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 31, 2026, 11:06 PM EDT
Completed Not applicable Interventional

Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients

NCT00002174
View directory record Official record
Conditions
HIV Infections
Interventions
Thalidomide
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 31, 2026, 11:06 PM EDT
Completed Phase 2 Interventional

GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

NCT01435226
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
GS-5885, GS-9451, tegobuvir, placebo to match tegobuvir, placebo to match RBV, Ribavirin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
37
States / cities
Tucson, Arizona • Anaheim, California • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 31, 2026, 11:06 PM EDT
Recruiting Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

NCT04301076
View directory record Official record
Conditions
Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, HTLV-1 Infection
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide, Lenalidomide, Multigated Acquisition Scan, Positron Emission Tomography, Prednisone, Vincristine Sulfate
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
19
States / cities
Atlanta, Georgia • City of Saint Peters, Missouri • Creve Coeur, Missouri + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 11:06 PM EDT
Completed Not applicable Interventional Results available

Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection

NCT02707991
View directory record Official record
Conditions
HIV, Hepatitis C, Chronic
Interventions
Nurse Case Management
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Oct 31, 2026, 11:06 PM EDT
Completed Phase 4 Interventional

QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

NCT00232908
View directory record Official record
Conditions
HIV Infections
Interventions
ARV regimen, enfuvirtide [Fuzeon]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
103
States / cities
Phoenix, Arizona • Bakersfield, California • Berkeley, California + 78 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 31, 2026, 11:06 PM EDT
Completed No phase listed Observational

Trimethoprim-Sulfamethoxazole vs Levofloxacin as Targeted Therapy for Stenotrophomonas Maltophilia Infections: a Retrospective Cohort Study

NCT04639817
View directory record Official record
Conditions
Stenotrophomonas Infection
Interventions
Levofloxacin, trimethoprim-sulfamethoxazole
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
1,621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 31, 2026, 11:06 PM EDT
Completed Phase 1 Interventional

Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B

NCT04629976
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
NCO-48 Fumarate 4 mg, NCO-48 Fumarate 20 mg, Tenofovir Alafenamide 25 mg
Drug
Lead sponsor
Nucorion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Monterey Park, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 31, 2026, 11:06 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection

NCT04372017
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
Hydroxychloroquine, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 31, 2026, 11:06 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

LMN-201 for Prevention of C. Difficile Infection Recurrence

NCT05330182
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
LMN-201, Placebo
Drug
Lead sponsor
Lumen Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
15
States / cities
Escondido, California • Hamden, Connecticut • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 31, 2026, 11:06 PM EDT
Completed Not applicable Interventional Results available

Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures

NCT01898208
View directory record Official record
Conditions
Bacteremia, Fungemia, Bloodstream Infection
Interventions
FilmArray testing, Antimicrobial Stewardship, Bacterial culture, Susceptibility testing
Device · Behavioral · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Up to 99 Years
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Oct 31, 2026, 11:06 PM EDT
Not yet recruiting Not applicable Interventional

Implementation of an Opt-Out Testing and Rapid Diagnostic Strategy for Syphilis and HIV in Pregnant Patients Presenting to the Emergency Department

NCT07525076
View directory record Official record
Conditions
HIV Infections, Syphilis Infection
Interventions
Chembio HIV/Syphilis rapid Point of Care (POC) test, Laboratory-based HIV and syphilis testing
Diagnostic Test
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
14 Years to 45 Years · Female only
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 31, 2026, 11:06 PM EDT
Completed Not applicable Interventional

Computer-Assisted Provision of Reproductive Health Care

NCT00829517
View directory record Official record
Conditions
Contraception, Sexually Transmitted Diseases
Interventions
computer-assisted provision of hormonal contraception, STI module
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
814 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
San Francisco, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 31, 2026, 11:06 PM EDT
Completed No phase listed Observational

Adherence and Clinical Correlates in Persons With HIV on TAF

NCT05335590
View directory record Official record
Conditions
Hiv
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 31, 2026, 11:06 PM EDT
Completed Phase 2 Interventional Results available

Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery

NCT01969058
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Isotretinoin
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 31, 2026, 11:06 PM EDT
Completed Not applicable Interventional

Integrating HCV and HIV Screening During the Era of HIV Antigen Testing

NCT02869776
View directory record Official record
Conditions
HIV, Hepatitis C
Interventions
Questionnaire, Rapid finger stick, Venipuncture
Behavioral · Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 31, 2026, 11:06 PM EDT
Completed Phase 2 Interventional Results available

Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

NCT00339040
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV), Placebo/QHPV
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
7 Years to 12 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
32
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 31, 2026, 11:06 PM EDT
Completed Phase 3 Interventional Results available

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

NCT00529568
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
eltrombopag, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
59
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 31, 2026, 11:06 PM EDT
Completed No phase listed Observational

Zepatier in Patients with Substance Use

NCT04048850
View directory record Official record
Conditions
Hepatitis C, Hiv, Coinfection, HIV, Substance Use Disorders
Interventions
Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 31, 2026, 11:06 PM EDT
Recruiting Phase 4 Interventional

Topical Steroids to Prevent Recurrent Urinary Tract Infections in Uncircumcised Male Infants: a Pilot Study

NCT07508124
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
betamethasone valerate 0.1% cream, Placebo cream
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
0 Months to 5 Months · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 31, 2026, 11:06 PM EDT
Completed No phase listed Observational

Charlotte Retention in Care Study

NCT03584048
View directory record Official record
Conditions
HIV I Infection
Interventions
Alert to provider
Other
Lead sponsor
Epividian
Industry
Eligibility
18 Years and older
Enrollment
6,500 participants
Timeline
2018 – 2019
U.S. locations
4
States / cities
Charlotte, North Carolina • Huntersville, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 31, 2026, 11:06 PM EDT